The patient has evidence of active vasculitis as assessed by increased reactivity in at least one of ESR, CRP, ANCA or BVAS compared to level after Ig therapy. AND A description of the relapse and active vasculitis requiring treatment is provided Review ANCA positive systemic necrotising ANCA positive systemic necrotising vasculitis failing to The review criteria have been simplified and Criteria vasculitis failing to respond to respond to corticosteroids and cytotoxic streamlined but content is largely corticosteroids and cytotoxic immunosuppression unchanged. Patients will still only receive six immunosuppression month’s treatment initially, and will then be Six-month’s treatment is authorised for patients in the required to requalify under the relapse first instance. The reporting of clinical outcome data is indication if more treatment is required. Six-month’s treatment is encouraged as demonstrated clinical response to Ig authorised for patients in the first therapy is required for eligibility for further instance, and no review is required. authorisation, should the patient relapse in the future. The reporting of clinical outcome Clinical effectiveness of Ig therapy may be demonstrated data is encouraged as by: demonstrated clinical response to Reduction in at least one indicator of Erythrocyte Ig therapy is required for eligibility Sedimentation Rate(ESR) C-reactive protein for further authorisation, should (CRP) level, ANCA Level or Birmingham Vasculitis the patient relapse in the future. Activity Score (BVAS) (<50%) or other indicator of active disease compared to the qualifying value Outcome measures Evidence of clinical benefit and response to treatment is assessed
The patient has evidence of active vasculitis as assessed by increased reactivity in at least one of ESR, CRP, ANCA or BVAS compared to level after Ig therapy. AND A description of the relapse and active vasculitis requiring treatment is provided Review Criteria ANCA positive systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression Six-month’s treatment is authorised for patients in the first instance, and no review is required. The reporting of clinical outcome data is encouraged as demonstrated clinical response to Ig therapy is required for eligibility for further authorisation, should the patient relapse in the future. Outcome measures Evidence of clinical benefit and response to treatment is assessed ANCA positive systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression Six-month’s treatment is authorised for patients in the first instance. The reporting of clinical outcome data is encouraged as demonstrated clinical response to Ig therapy is required for eligibility for further authorisation, should the patient relapse in the future. Clinical effectiveness of Ig therapy may be demonstrated by: Reduction in at least one indicator of Erythrocyte Sedimentation Rate(ESR) C-reactive protein (CRP) level, ANCA Level or Birmingham Vasculitis Activity Score (BVAS) (<50%) or other indicator of active disease compared to the qualifying value The review criteria have been simplified and streamlined but content is largely unchanged. Patients will still only receive six month’s treatment initially, and will then be required to requalify under the relapse indication if more treatment is required.
Immunology-Ch6-Anti-neutrophil-cytoplasmic-antibody-%28ANCA%29.DOCX